Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4096-4099
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4096
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4096
Table 1 Baseline characteristics of the patients
Patient | Sex | Age(yr) | Liverbiopsy | Complica-tions | HBV DNA(pg/mL )1 | LAM3(wk) | YMDD |
1 | F | 77 | Cirrhosis | HCC | 8 | 96 | M204I |
2 | M | 40 | CAH Ishak 9;2 | 2 | 156 | M204V | |
3 | M | 63 | Cirrhosis | Undetectable2 | 188 | M204V | |
4 | F | 68 | Cirrhosis | F2 esoph varices | 1600 | 44 | M204I |
5 | M | 55 | Cirrhosis | Undetectable2 | 104 | M204V, L180M | |
6 | F | 58 | Cirrhosis | 450 | 88 | WT | |
7 | M | 68 | Cirrhosis | F2 esoph varices | 64 | 76 | WT |
8 | M | 57 | CAH Ishak 7; 4 | 162 | 116 | WT | |
9 | M | 65 | Cirrhosis | 78 | 88 | WT | |
10 | M | 58 | Cirrhosis | 0.2 | 52 | WT | |
11 | F | 75 | Cirrhosis | 3.100 | 116 | WT |
Table 2 Results of treatment with tenofovir disoproxil fumarate (TDF) in the individual patients
Patient(YMDD/WT) | BasalHBVDNA1(cp/mL) | Durationoftreatmentwith TDF(wk) | HBVDNA(end ofTDF)( cp/mL) | Drugsubstituted for TDF | HBV DNAaftersubstitutionof TDF |
1 (YMDD) | 1000-2000 | 96 | < 1000 | ADV | 130.000 cp/mL |
2 (YMDD) | 4.8 × 106 | 144 | < 1000 | ADV | No viral |
rebound | |||||
3 (YMDD) | 1000-2000 | 56 | < 1000 | LAM | No viral |
rebound | |||||
4 (YMDD) | 1000-2000 | 80 | < 10002 | ADV + LAM | No viral |
rebound | |||||
5 (YMDD) | 1000-2000 | 60 | < 1000 | ADV | No viral |
rebound | |||||
6 WT | < 1000 | 108 | < 1000 | ADV | No viral |
rebound | |||||
7 WT | < 1000 | 76 | < 1000 | ADV | 21 000 cp/mL |
8 WT | < 1000 | 88 | < 1000 | ADV | 2700 cp/mL |
9 WT | < 1000 | 116 | < 1000 | ADV | No viral |
rebound | |||||
10 WT | < 1000 | 52 | < 1000 | LAM added to | No viral |
TDF | rebound | ||||
11 WT | < 1000 | 24 | < 1000 | LAM | No viral |
rebound |
- Citation: Poggio PD, Zaccanelli M, Oggionni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J Gastroenterol 2007; 13(30): 4096-4099
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4096.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4096